Recursion Pharmaceuticals, Inc ( ($RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Recursion Pharmaceuticals (RXRX) saw a sharp uptick in trading as investors looked ahead to the CEO's upcoming presentation at a major AI conference. The focus is on how the company’s AI strategy and ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...